JP2000507574A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507574A5
JP2000507574A5 JP1997535252A JP53525297A JP2000507574A5 JP 2000507574 A5 JP2000507574 A5 JP 2000507574A5 JP 1997535252 A JP1997535252 A JP 1997535252A JP 53525297 A JP53525297 A JP 53525297A JP 2000507574 A5 JP2000507574 A5 JP 2000507574A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997535252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507574A (ja
Filing date
Publication date
Priority claimed from US08/626,524 external-priority patent/US5837829A/en
Application filed filed Critical
Publication of JP2000507574A publication Critical patent/JP2000507574A/ja
Publication of JP2000507574A5 publication Critical patent/JP2000507574A5/ja
Withdrawn legal-status Critical Current

Links

JP9535252A 1996-04-02 1997-02-06 ９―オキシムシリルエリトロマイシンａ誘導体 Withdrawn JP2000507574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/626,524 1996-04-02
US08/626,524 US5837829A (en) 1996-04-02 1996-04-02 9-oximesilyl erythromycin a derivatives
PCT/US1997/001955 WO1997036913A1 (en) 1996-04-02 1997-02-06 9-oximesilyl erythromycin a derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007100369A Division JP2007224035A (ja) 1996-04-02 2007-04-06 ９―オキシムシリルエリトロマイシンａ誘導体

Publications (2)

Publication Number Publication Date
JP2000507574A JP2000507574A (ja) 2000-06-20
JP2000507574A5 true JP2000507574A5 (enExample) 2004-11-25

Family

ID=24510750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9535252A Withdrawn JP2000507574A (ja) 1996-04-02 1997-02-06 ９―オキシムシリルエリトロマイシンａ誘導体
JP2007100369A Pending JP2007224035A (ja) 1996-04-02 2007-04-06 ９―オキシムシリルエリトロマイシンａ誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007100369A Pending JP2007224035A (ja) 1996-04-02 2007-04-06 ９―オキシムシリルエリトロマイシンａ誘導体

Country Status (10)

Country Link
US (1) US5837829A (enExample)
EP (1) EP0891371B1 (enExample)
JP (2) JP2000507574A (enExample)
AT (1) ATE256138T1 (enExample)
CA (1) CA2250771C (enExample)
DE (1) DE69726714T2 (enExample)
DK (1) DK0891371T3 (enExample)
ES (1) ES2212808T3 (enExample)
PT (1) PT891371E (enExample)
WO (1) WO1997036913A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004574A1 (en) 1996-07-29 1998-02-05 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2274799A (en) * 1997-12-22 1999-07-12 Biochemie S.A. Intermediates in macrolide production
KR100283990B1 (ko) * 1998-12-29 2001-03-02 민경윤 에리스로마이신 a 유도체 및 그의 제조방법
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
HUP0204091A3 (en) 1999-12-16 2003-05-28 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph iv and pharmaceutical composition containing them and their use
JP2003519661A (ja) 2000-01-11 2003-06-24 テバ ファーマシューティカル インダストリーズ リミティド クラリスロマイシンの多形の製造方法
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
HRP20020709A2 (en) 2000-02-29 2004-12-31 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
ATE338053T1 (de) * 2000-03-15 2006-09-15 Hanmi Pharm Ind Co Ltd Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) * 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
EP0260938B1 (en) * 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for preparing the same
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001506895A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2001506870A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2001510462A5 (enExample)
JP2000502425A5 (enExample)
JP2001507336A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000507574A5 (enExample)
JP2000516579A5 (enExample)
JP2000500857A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000500318A5 (enExample)
JP2000502479A5 (enExample)
JP2001503989A5 (enExample)